{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:59:50Z","timestamp":1793818790206,"version":"4.6.1"},"reference-count":39,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,11]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome characterized by excessive immune cell activation and hypersecretion of inflammatory cytokines, many of which signal via the Janus kinases (JAKs). Preclinical studies have demonstrated that the JAK1\/2 inhibitor ruxolitinib ameliorates disease manifestations and prolongs survival in mouse models of HLH. Similarly, clinical studies have shown preliminary evidence of efficacy for treatment of HLH in children; however, prospective trials evaluating optimal ruxolitinib doses in HLH in pediatric are lacking. To address this gap, we developed HLHRUXO, a prospective clinical trial using a ruxolitinib-containing regimen for children with HLH. Patients received ruxolitinib 25 mg\/m2 twice daily combined with dexamethasone, with or without etoposide, for 8 weeks, followed by continuation therapy at the discretion of the treating physician. Pharmacokinetic studies were performed on days 1 and 8. A total of 8 patients (average age, 7.6 years; 5 with primary HLH pHLH], and 3 with secondary HLH [sHLH]) completed the study; no patients experienced dose-limiting adverse events. All patients experienced a favorable response at 1 week, demonstrating clinical stabilization and improvement in serum ferritin levels. Furthermore, all 5 patients with newly diagnosed HLH (3 with pHLH, 2 with sHLH) achieved a complete response (CR) by 8 weeks, and all were alive at 1 year. One patient with relapsed\/refractory sHLH achieved a CR at 8 weeks and was alive at 1 year, whereas 2 others with relapsed\/refractory pHLH died. Our findings confirm the safety of this ruxolitinib-containing regimen for pediatric HLH, with the best results observed in patients with newly diagnosed disease. Further studies of ruxolitinib as frontline therapy for children with HLH are warranted. This trial was registered at www.clinicaltrials.gov as NCT04551131.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026020265","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T20:56:52Z","timestamp":1780606612000},"page":"5308-5318","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["HLHRUXO: a prospective trial of a ruxolitinib-containing regimen for children with hemophagocytic lymphohistiocytosis"],"prefix":"10.1182","volume":"10","author":[{"given":"Lauren K.","family":"Meyer","sequence":"first","affiliation":[{"name":"1Department of Pediatrics, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5914-5058","authenticated-orcid":false,"given":"Kristen","family":"Ryan","sequence":"additional","affiliation":[{"name":"2Department of Surgery, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Panetta","sequence":"additional","affiliation":[{"name":"3Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7558-558X","authenticated-orcid":false,"given":"Kristine R.","family":"Crews","sequence":"additional","affiliation":[{"name":"3Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrin","family":"Albeituni","sequence":"additional","affiliation":[{"name":"4Department of Oncology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara A.","family":"Degar","sequence":"additional","affiliation":[{"name":"5Dana-Farber\/Boston Children\u2019s Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1790-2679","authenticated-orcid":false,"given":"Michelle L.","family":"Hermiston","sequence":"additional","affiliation":[{"name":"6Department of Pediatrics, University of California, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie-An M.","family":"Talano","sequence":"additional","affiliation":[{"name":"7Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3511-8896","authenticated-orcid":false,"given":"Lilibeth L.","family":"Torno","sequence":"additional","affiliation":[{"name":"8Hyundai Cancer Institute, Children\u2019s Hospital of Orange County, Orange, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias T.","family":"Zambidis","sequence":"additional","affiliation":[{"name":"9Department of Oncology, Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4019-7440","authenticated-orcid":false,"given":"Deni J.","family":"Trone","sequence":"additional","affiliation":[{"name":"3Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah D.","family":"Sabin","sequence":"additional","affiliation":[{"name":"10Department of Radiology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5247-5399","authenticated-orcid":false,"given":"Gabriela","family":"Maron","sequence":"additional","affiliation":[{"name":"11Department of Infectious Diseases, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Flerlage","sequence":"additional","affiliation":[{"name":"12Department of Pediatrics, University of Rochester Medical Center, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Thomas","sequence":"additional","affiliation":[{"name":"13Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Cheng","sequence":"additional","affiliation":[{"name":"14Department of Biostatistics, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2198-5991","authenticated-orcid":false,"given":"Patrick K.","family":"Campbell","sequence":"additional","affiliation":[{"name":"4Department of Oncology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5581-6555","authenticated-orcid":false,"given":"Kim E.","family":"Nichols","sequence":"additional","affiliation":[{"name":"4Department of Oncology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa R.","family":"Hines","sequence":"additional","affiliation":[{"name":"15Department of Pediatric Medicine, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"2026081110270421000_bib1","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-041610-134208","article-title":"Familial and acquired hemophagocytic lymphohistiocytosis","volume":"63","author":"Janka","year":"2012","journal-title":"Annu Rev Med"},{"issue":"1","key":"2026081110270421000_bib2","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jaci.2015.06.048","article-title":"Genetic predisposition to hemophagocytic lymphohistiocytosis: report on 500 patients from the Italian registry","volume":"137","author":"Cetica","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2026081110270421000_bib3","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1073\/pnas.0509054103","article-title":"Perforin-dependent elimination of dendritic cells regulates the expansion of antigen-specific CD8+ T cells in vivo","volume":"103","author":"Yang","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2026081110270421000_bib4","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1182\/blood-2010-12-324533","article-title":"Perforin is a critical physiologic regulator of T-cell activation","volume":"118","author":"Lykens","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2026081110270421000_bib5","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1084\/jem.20140964","article-title":"Failed CTL\/NK cell killing and cytokine hypersecretion are directly linked through prolonged synapse time","volume":"212","author":"Jenkins","year":"2015","journal-title":"J Exp Med"},{"issue":"3","key":"2026081110270421000_bib6","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood-2003-10-3413","article-title":"An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder","volume":"104","author":"Jordan","year":"2004","journal-title":"Blood"},{"key":"2026081110270421000_bib7","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jcrc.2017.02.018","article-title":"Cytokine profiles as novel diagnostic markers of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children","volume":"39","author":"Han","year":"2017","journal-title":"J Crit Care"},{"issue":"13","key":"2026081110270421000_bib8","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/blood-2017-12-820852","article-title":"Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome","volume":"131","author":"Weiss","year":"2018","journal-title":"Blood"},{"issue":"17","key":"2026081110270421000_bib9","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1182\/bloodadvances.2021004287","article-title":"IFN-\u03b3 signature in the plasma proteome distinguishes pediatric hemophagocytic lymphohistiocytosis from sepsis and SIRS","volume":"5","author":"Lin","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"2026081110270421000_bib10","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.hoc.2025.03.002","article-title":"Role of hematopoietic cell transplantation in pediatric and adult hemophagocytic lymphohistiocytosis-remaining unknowns and challenges","volume":"39","author":"Nikiforow","year":"2025","journal-title":"Hematol Oncol Clin North Am"},{"issue":"5","key":"2026081110270421000_bib11","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/(SICI)1096-911X(199705)28:5<342::AID-MPO3>3.0.CO;2-H","article-title":"HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society","volume":"28","author":"Henter","year":"1997","journal-title":"Med Pediatr Oncol"},{"issue":"2","key":"2026081110270421000_bib12","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"17","key":"2026081110270421000_bib13","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1182\/blood-2011-06-356261","article-title":"Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol","volume":"118","author":"Trottestam","year":"2011","journal-title":"Blood"},{"issue":"25","key":"2026081110270421000_bib14","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1182\/blood-2017-06-788349","article-title":"Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study","volume":"130","author":"Bergsten","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2026081110270421000_bib15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/pbc.24188","article-title":"Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab","volume":"60","author":"Marsh","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2026081110270421000_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26308","article-title":"Salvage therapy for refractory hemophagocytic lymphohistiocytosis: a review of the published experience","volume":"64","author":"Marsh","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"2026081110270421000_bib17","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"2026081110270421000_bib18","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1002\/art.24567","article-title":"The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo","volume":"60","author":"Kremer","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"34","key":"2026081110270421000_bib19","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO-25-00809","article-title":"Ruxolitinib versus best available therapy in patients with steroid-refractory acute graft-versus-host disease: final analysis from the randomized phase III REACH2 trial","volume":"43","author":"Mohty","year":"2025","journal-title":"J Clin Oncol"},{"issue":"12","key":"2026081110270421000_bib20","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"issue":"10","key":"2026081110270421000_bib21","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/pbc.25575","article-title":"A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: a Children\u2019s Oncology Group phase 1 consortium study (ADVL1011)","volume":"62","author":"Loh","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"13","key":"2026081110270421000_bib22","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood-2015-12-684399","article-title":"Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis","volume":"127","author":"Das","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2026081110270421000_bib23","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2016-02-700013","article-title":"Therapeutic effect of JAK1\/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice","volume":"128","author":"Maschalidi","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2026081110270421000_bib24","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1182\/blood.2019000761","article-title":"Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis","volume":"134","author":"Albeituni","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2026081110270421000_bib25","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1182\/blood.2020006075","article-title":"JAK\/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation","volume":"136","author":"Meyer","year":"2020","journal-title":"Blood"},{"issue":"24","key":"2026081110270421000_bib26","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1182\/blood.2021014860","article-title":"A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis","volume":"139","author":"Zhang","year":"2022","journal-title":"Blood"},{"issue":"23","key":"2026081110270421000_bib27","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood.2023021046","article-title":"Differential effects of itacitinib, fedratinib, and ruxolitinib in mouse models of hemophagocytic lymphohistiocytosis","volume":"143","author":"Keenan","year":"2024","journal-title":"Blood"},{"issue":"12","key":"2026081110270421000_bib28","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1002\/ajh.70081","article-title":"Ferritin, C-reactive protein, and soluble CD25 distinguish TAFRO from HLH","volume":"100","author":"Rowe","year":"2025","journal-title":"Am J Hematol"},{"issue":"22","key":"2026081110270421000_bib29","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood.2024025077","article-title":"Diagnostic guidelines for familial hemophagocytic lymphohistiocytosis revisited","volume":"144","author":"Henter","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2026081110270421000_bib30","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13045-024-01621-x","article-title":"Hemophagocytic lymphohistiocytosis: current treatment advances, emerging targeted therapy and underlying mechanisms","volume":"17","author":"Wu","year":"2024","journal-title":"J Hematol Oncol"},{"issue":"suppl 1","key":"2026081110270421000_bib31","doi-asserted-by":"crossref","first-page":"LBA-6","DOI":"10.1182\/blood-2018-120810","article-title":"Safety and efficacy of emapalumab in pediatric patients with primary hemophagocytic lymphohistiocytosis","volume":"132","author":"Locatelli","year":"2018","journal-title":"Blood"},{"issue":"3","key":"2026081110270421000_bib32","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1124\/dmd.108.023630","article-title":"Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-alpha or interleukin-6","volume":"37","author":"Le Vee","year":"2009","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"2026081110270421000_bib33","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood.2023022281","article-title":"Survival in primary hemophagocytic lymphohistiocytosis, 2016 to 2021: etoposide is better than its reputation","volume":"143","author":"B\u00f6hm","year":"2024","journal-title":"Blood"},{"issue":"4","key":"2026081110270421000_bib34","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s12185-020-02936-4","article-title":"Short-term effectiveness of ruxolitinib in the treatment of recurrent or refractory hemophagocytic lymphohistiocytosis in children","volume":"112","author":"Wei","year":"2020","journal-title":"Int J Hematol"},{"issue":"3","key":"2026081110270421000_bib35","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s00277-025-06336-8","article-title":"CXCL9 and IL-18: potential biomarkers for efficacy evaluation in refractory hemophagocytic lymphohistiocytosis treated with RED (ruxolitinib, emapalumab and dexamethasone)","volume":"104","author":"Lan","year":"2025","journal-title":"Ann Hematol"},{"issue":"4","key":"2026081110270421000_bib36","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjh.17331","article-title":"Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory\/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial","volume":"193","author":"Wang","year":"2021","journal-title":"Br J Haematol"},{"issue":"2","key":"2026081110270421000_bib37","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/MPG.0000000000003807","article-title":"The liver in hemophagocytic lymphohistiocytosis: not an innocent bystander","volume":"77","author":"Diamond","year":"2023","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026081110270421000_bib38","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jpeds.2022.07.006","article-title":"High prevalence of hemophagocytic lymphohistiocytosis in acute liver failure of infancy","volume":"250","author":"Had\u017ei\u0107","year":"2022","journal-title":"J Pediatr"},{"issue":"5","key":"2026081110270421000_bib39","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood.2024024362","article-title":"Ruxolitinib targets JAK-STAT signaling to modulate neutrophil activation in refractory macrophage activation syndrome","volume":"146","author":"Ma","year":"2025","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/15\/5308\/2536125\/blooda_adv-2026-020265-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/15\/5308\/2536125\/blooda_adv-2026-020265-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:43:36Z","timestamp":1786463016000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/15\/5308\/568877\/HLHRUXO-a-prospective-trial-of-a-ruxolitinib"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":39,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2026,8,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020265","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,11]]},"published":{"date-parts":[[2026,7,31]]}}}